Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
about
Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assayChallenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico.Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins.Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.Analytical comparability study of recombinant monoclonal antibody therapeutics.
P2860
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@ast
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@en
type
label
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@ast
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@en
prefLabel
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@ast
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@en
P2093
P2860
P1433
P1476
Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics
@en
P2093
Christine Bryson
Gregory C Flynn
Helen Reynolds
Jonathan Herskovitz
Linda O Narhi
Marisa K Joubert
Matthew P Baker
P2860
P304
P356
10.1371/JOURNAL.PONE.0159328
P407
P577
2016-08-05T00:00:00Z